Kyverna continues to explore KYV-101 in numerous autoimmune disorders, including multiple sclerosis (MS) and rheumatoid arthritis (RA), through its own trials and investigator-initiated studies, providing a broad platform for indication expansion. Kyverna is also investing in next-generation cell therapy platforms with KYV-102, which retains the KYV-101 CAR construct while using a whole blood, rapid manufacturing process. The company remains on schedule to file an IND in the fourth quarter of 2025.Furthermo ...